Enleofen co-founders identify IL-11 as pulmonary fibrosis target
INDICATION: Pulmonary fibrosis
A National Heart Centre Singapore team led by Enleofen Bio Pte. Ltd. co-founders Stuart Cook and Sebastian Schafer showed that inhibiting IL-11 could treat pulmonary fibrosis. Levels of IL-11 mRNA were higher in lung samples from 122 IPF patients than in samples from 92 healthy volunteers, and among the patients, high IL-11 mRNA levels were associated with poor lung function and elevated levels of the fibrosis marker collagen type I α1 (COL1A1) mRNA. Enleofen's anti-IL-11 mAb ENx203 reduced migration and invasiveness in primary mouse lung fibroblasts. In mice with drug-induced pulmonary fibrosis, ENx203 or systemic knockout of IL-11 receptor reduced collagen deposition and histological signs of parenchymal disruption in the lung...